















Brittle asthma, even though it is thought to be a rare form of Asthma, may form the bulk of our difficult to 
treat asthma and frequently unresponsive exacerbation. Brittle Asthma. Brittle asthma is a rare form of 
1severe asthma characterized by a wide variation of Peak Expiratory Flow (PEF),  in spite of high doses of 
inhaled steroids and bronchodilator therapy. Brittle asthmatic patients have very serious and often, life 
threatening, attacks. There are two forms of brittle asthma.
CASE PRESENTATION 
We present the cases of a  45yr old Nurse anesthetics who was diagnosed >5yrs ago and a 56yr old 
unemployed who was diagnosed >15yrs ago. Both have been stable for years on add on maintenance 
therapy with high doses of inhaled corticosteroid and β  agonist as oral salbutamol and an inhaler therapy 2
during exacerbation. Recently, both patients noticed worsening of symptoms despite high dose therapy, 
They have been in and out of hospital recently for uncontrolled asthma. They later had to be admitted in ICU 
because of respiratory insufficiency. These two lapsed into brittle asthma with recurrent bronchospasm, due 
to repeated exposure to anesthetic agents and environmental exposure at home respectively.
KEY WORD: Brittle Asthma, Peak Expiratory Flow (PEF), Respiratory Insufficiency, environmental exposure.
Case Report
INTRODUCTION
sthma is a chronic inammatory disease 
Aof the airways. It is characterized by variable airow obstruction which is 
reversible either spontaneously or with 
treatment. The chronic inammation of airways 
causes  an  increase  o f  bronchia l  hyper 
responsiveness in response to variety of stimuli.
Asthma causes recurrent episodes of coughing, 
wheezing, chest tightness and breathlessness. 
Brittle asthma is very difcult to recognize and to 
treat, it is a rare form of severe asthma that the 
clinicians may recognize and treat strictly, 
because of high morbidity and mortality 
1
associated with it. 
Asthma is a heterogeneous disease. Since 1977, 
the term brittle asthma has been used in different 
ways by different physicians, leading to some 
confusion over whether such a group is truly 
separable from other patients at the severe end of 
the asthma spectrum. In order to try and clarify 
this area a classication of brittle asthma into two 
types based on its distinct phenotypes were 
2 
made. It merely accounts for 0.05% of asthmatic 
2population.  It is characterized by wide variability 
of PEF despite taking high dose of corticosteroids. 
Patients with variation of PEF are on increased 
risk of mortality. The exact mortality of brittle 
3, 4asthma is not known, . Depending upon peak 
expiratory ow rate, it is classied into two types 
namely type 1 and type 2: 
Type 1 brittle asthma is characterized by a 
maintained wide PEF variability (> 40% diurnal 
variation for > 50% of the time over a period of at 
least 150 days) despite considerable medical 
therapy including a dose of inhaled steroids of at 
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least 1500 pg of beclomethasone or equivalent. 
It is common between the age of 15 and 55 years, 
with more females to males ratio (F2.5:M1) (Table 
1). It is associated with positive skin prick tests and 
intolerance to some food items e.g wheat and dairy 
products (Table 2) Several studies have shown 
some degree of relationship between Brittle 
asthma and personality disorders. Type 2 brittle 
asthma is characterized by acute attacks that are 
very severe and could lead to mortality or 
admission into intensive care unit (ICU) and use of 
















Table 1: Patients' characteristics with brittle asthma










































Table 2. Positive food challenge in Brittle Asthma 


































Type 1 brittle asthma has increase in hospital visit 
for admissions or assessment and stabilization of 
asthma. The patients with type 1 brittle asthma are 
taking a considerable amount of medications, 
such as inhaled steroid and bronchodilator, or oral 
steroids, with attendant adverse effects. They 
have increase rate of developing esophageal 
reux, osteoporosis, weight gain, that increase 
3, 5
their morbidity. 
Type 2 brittle asthma is associated with increase in 
hospital admission for acute severe attack, and is 
associated with a high mortality. The patients with 
type 2 normally remain stable for a long period, 
but when they have an attack, it is very severe, and 
3may require assisted ventilation .
The diagnosis of brittle asthma involves PEF 
monitoring and assessment for the factors 
responsible for poor control of asthma. Majority 
(60%) of most patients with type 1 brittle asthma 
5are intolerant to wheat and diary product  
however, psychosocial factors, co- morbid 
condition like congestive cardiac failure, COPD, 
low socio economy, poor quality of life and 
asthma related events are  commonly associated 
 6 ,  7 ,  8
with britt le asthma among patients . 
Immunoglobul in  deciency ,  autonomic 
imbalance and relative resistance to anti 
inammatory action of steroids are also 
9considered to be associated factors .
Identifying and avoiding the allergen exposure is 
critical in the management and treatment of brittle 
asthma. Long term subcutaneous β2 agonist has 
often resulted in improvement in symptoms and 
10
variation of PEF in 50% patients . Effectiveness of 
alternative immunomodulatory treatment in 
steroid resistant brittle asthmatic patients has not 
10,11been elucidated so far.
Type 1 brittle asthma is associated with Atopy, 
demonstrated by a skin prick test positivity for cat, 
horse, wheat and chocolate. The reaction to 
Dermatophagoidespteronyssinus is greater in type 1, 
but seen only in varying frequencies. Many 
patients in this group report history of intolerance, 
to peanuts, sh and wheat. Type 2 brittle asthma 
may worsen after exposure to fungal spores such 
11as Alternaria. 
Both patients with type 1 and 2 brittle asthma have 
a reduced perception of worsening airways 
11, 12
obstruction, and a reduced hypoxic drive. 
An important mechanism in brittle asthma is 
airway smooth muscle contraction that is 
activated rapidly by a cholinergic reex, and by 
local release of bradykinins, substance P. bronco 
constrictor and inammatory peptides. Many 
allergens might enhance this mechanism, also 
edema formation due to vasodilatation, plasma 
exudation could lead to acute airway narrowing in 
12
brittle asthma.  The smooth muscle is also 
remodeled in severe asthma and is seen much in 
bronchial walls of patients that died from 
asthmatic attack. Bronchial biopsy shows 
thickening of the subbasement membrane, 
irreversible changes in smooth muscle, and 
glandular componentscontribute to stable and 
irreversible obstruction of airways. Neutrophils 
predominance over eosinophils as early changes 
12
has also been observed.  Altered steroid response 
13
is also considered in brittle asthma. 
















A 45yr old male nurse anesthetic who was 
diagnosed 5years ago with asthma and was on 
controller therapy. He was admitted into the 
Emergency Room (ER) with history of cough, 
shortness of breath, chest tightness, wheeze. His 
symptoms have worsened over the last 2 days 
despite been on high dose of corticosteroid (oral 
prednisolone 20mg twice a day) and β  agonist 2
(salbutamol 4mg twice a day), he has been 
admitted in the hospital for ecxercabation about 12 
times in the last 6 months.
Patient is an anesthetic nurse who  has been 
working in the hospital theatre for 10 years, he 
puts in an average 10 hours per day and attend to 
average of 10 surgery cases 3 times every week. 
Patient admits repeated exposure to anesthetic 
agents. 
 About 4months prior to this admission he was 
treated for acute ecxercabation with 100% O2,  
intravenous uid (normal saline) and 10mg 
nebulized salbutamol over 2 hours  and IV 
Hydrocortisone 100mg stat then daily for 72 hours 
in addition to macrolide antibiotics Erythromycin 
500mg thrice daily for 5 days. He did well and was 
discharged from emergency room, patient was 
maintained on inhaled corticosteroid and long 
acting agonist as maintenance therapy, Patient β2
was advised on avoidance of smoke, dusty 
environment including reduction in number of 
hours exposed to anesthetic agent. He had 
r e m a i n e d  s t a b l e  e x c e p t  f o r  o c c a s i o n a l 
ecxercabation during rainy season and Hamattan 
periods and winter periods.
On Physical examination the patient was alert, 
conscious, tachypnic and anxious. The blood 
pressure was 140/90mmhg with a respiratory rate 
of 30bpm. Cardiovascular function was recorded 
to be normal. Lung examination showed 
generalized rhonchi, prolong expiratory phase, 
bronchial breath sound and coarse crepitation. 
SPO of 78%.2 
9White blood count was 9.5 x 10 /µL with 
eosinophilia (30%) and high neutrophil count 
(68%) suggesting allergen hypersensitivity due to 
environmental exposure and respiratory tract 
infection as the possible predisposing factors for 
acute asthmatic episode. Peak Expiratory Flow 
(PEFR) was 250L which was far less for his 
predicted age and height (160cm) of 590l/min. 
serum electrolyte, urea and createnine were 
within normal range, Chest Xray shows 
hyperination and hyper lucent lung elds.
CASE 2
A 56yr old unemployed who was diagnosed 
>15yrs ago,  has been stable for years on add on 
maintenance therapy with high doses of inhaled 
corticosteroid and β  agonist as (salbutamol ) and 2
salbutamol inhaler for use during exacerbation 
(PRN). He presented at the Emergency Room with 
sudden onset of breathlessness, tachypnea, fever 
and restlessness. He has been having repeated 
episode of attack in recent past with daily 
exacerbation of symptoms despite been on a high 
dose inhaled corticosteroid/ Long acting β2 
agonist (Fluticasone/ salmeterol) 250µg twice 
daily.
Physical examination reveals an acutely ill looking 
restless middle aged man who was dyspneic, 
febrile (t-37.8°C), he was dehydrated, cyanosed 
and anxious. 
Chest examinations revealed a wide spread 
expiratory wheeze with evidence of consolidation 
at the right infra mammary areas.
He had an SPO of 65% at room air, Respiratory- 2 
silent chest, PR 120bpm, BP 150/90mmhg, HR 105 
bpm
Chest X-ray revealed a hyper inated with hyper 
lucent lungs with homogenous opacities at the 
right lung base. Complete Blood count shows RBC 
9 9
5.6 X 10 , PCV 35%, WBC 11.0 X 10 , Neutrophils 
count was 68% with toxic granulocytosis, and 
Eosinophils was 16%.
Clinical and examination ndings were consistent 
with Brittle Asthma presenting in life threatening 
state precipitated by Respiratory tract infection
Patient was admitted to ICU and was given 100% 
O at 4l/min, IVF 5%destrose saline, he was also 2 
place on nebulised salbutamol 10mg and 
intravenous hydrocortisone 200mg stat and 
Ceftriaxone 2g stat the 12 hourly for 72 hours
DISCUSSION
These cases represent Brittle asthma with recurrent 
bronchospasm, severe acute exacerbation of 
bronchial asthma secondary to repeated exposure 
to anesthetic agents and repeated respiratory tract 
infection/environmental exposure to dust and 
particulate matter at home respectively.















Brittle asthma even though it is thought to be rare 
form of Asthma,  a lot of our difcult to treat 
asthma and frequent unresponsive exacerbation 
might just be hidden face of Brittle Asthma. It is 
very difcult to treat and often carries high 
mortality rates among Asthmatics. The patients 
with brittle asthma have poor adherence to the 
treatment and have to be monitored closely. The 
standard guidelines for asthma are not applicable, 
because the brittle asthmatic patients are taking 
high doses of inhaled steroids and bronchodilators, 
so when their conditions are worsening, they have 
14to take oral steroids.
The treatment for type1 brittle asthma begins with 
reduced allergen exposure, and avoidance foods 
for which the patients are intolerant to. Mineral 
supplements such as selenium, magnesium, anti-
oxidant and vitamins A, C, B have been found to 
15
reduce incidence of brittle asthma. 
The therapy is essentially based on high doses of 
inhaled corticosteroid, during acute attacks it is 
desirable to prescribe oral steroids and increase 
dose of β -agonist. Subcutaneous infusion of β -2 2
agonist, such as terbutaline at 6 and 15mg per day 
through a battery-powered syringe driver (CSIT). 
Adverse effects such as changes in serum 
potassium or glucose concentrations might 
abounds. Using this technique, around half of 
patients with type I brittle asthma show marked 
improvements in symptoms, variation in PEF and 
use of other asthma medication, including oral 
s t e r o i d  u s e .  A r o u n d  2 5  %  s h o w  s o m e 
improvement in symptoms but less improvement 
in PEF while the remaining does not respond. 
Chronic steroid-dependent asthmatics without 
intrinsic PEF variability do not respond to this 
16form of therapy.
Salmeterol has no proven efcacy in these patients 
for reasons that are not clear. Whether formeterol, 
which is a full agonist may be more useful than 
salmeterol, a partial agonist, remains to be 
determined.
The treatment of patients with type 2 brittle 
asthma, that are relatively symptom free, consists 
of avoidance of allergen exposure, identication 
of the triggers, self-management, and to treat the 
acute attacks with injection of adrenaline in a  
preloaded syringe.  These patients  have 
unexpected attacks, that requires emergency 
hospital admission, for acute respiratory 
insufciency and they may require assisted 
respiration through mechanical ventilation 
devices. Adrenaline may have theoretical 
advantages over selective 132 agonists, because of 
its action as an alpha adrenoceptor against 
reducing airway oedema as discussed in the 
section on acute airway narrowing above.
Preloaded syringes (Epi-Pen, ALK, UK; Ana Pen, 
Allerayde, UK) should be provided for emergency 
treatment. Inhaled adrenaline may be more 
effective than a selective 132 agonist inhaler. Once 
adrenaline has been injected the patient should be 
placed on a dose of nebulized salbutamol or 
terbutaline. Rapid onset attacks such as these are 
often equally quick to resolve leading to the 
opportunity for inadequate assessment of severity 
16in these cases. 
New therapy such as leukotriene receptor 
antagonists and 5-liposygenase inhibitors oral 
cyclosporine or methotrexate, or intra-venous 
immunoglobulin, may help the treatment in brittle 
asthma.
A good attention of physicians may help for 
psychological components of asthma and 
especially in brittle asthma, could inuence the 
disease. Environmental exposure to triggers like 
dust, chemical agents, working environment and 
chronic respiratory tract infection could explain 
why the two patients have developed Brittle 
asthma over time as a result of repeated exposure 
and treatment cycles. Respiratory tract infections 
are important triggers for asthma exacerbations in 
17,18
adults and children.  
Between 14% to 45 % acute exacerbation of asthma 
are thought to be associated with respiratory tract 
19, 20
infection in children.  Patients with hospital 
acquired pneumonia may remain totally 
2 1asymptomatic.  Chronic respiratory tract 
infection may well be the most likely reason 
behind the patient recent asthma exacerbation. 
Early diagnosis and aggressively treating 
respiratory tract infection can reduce risk of 
asthma exacerbation.
CONCLUSION
Diagnosis is based on the analysis of specic 
symptoms, role of triggers, personal or family 
history, measurement of lung function and PEF 















monitoring. Pharmacological treatment of type 1 
brittle asthma in addition to the high doses of 
inhaled and/or oral steroids and bronchodilators 
includes subcutaneous injections of beta2 agonist 
and inhalation of long acting beta2 agonist. The 
treatment of patients with type 2 brittle asthma 
includes exclusion of allergen exposure, 
identication of triggers, self-management and 
management of acute attacks. The patient was 
treated with multiple drug therapy and was 
advised to change working place and modify 
leaving environment
Patients with brittle asthma, whether type 1 or 
type 2, pose difcult and complex management 
problems. Trying to classify these severe patients 
will help to determine the differing factors 
involved and, while this classication will not 
embrace all patients with severe asthma, but can 
help to identify the possible causality and 
treatment of this high morbidity group. 
Individualized treatment approach is always 
advocated keeping in view the possible triggers 
and previous drug therapy, diet, psychological 
and environmental exposures.
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